 Cholesterol, LDL
"Cholesterol, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008078
|
| MeSH Number(s) |
D10.532.515.500 D10.570.938.208.275 D12.776.521.550.500
|
| Concept/Terms |
Cholesterol, LDL- Cholesterol, LDL
- Low Density Lipoprotein Cholesterol
- beta-Lipoprotein Cholesterol
- Cholesterol, beta-Lipoprotein
- beta Lipoprotein Cholesterol
- LDL Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, LDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, LDL".
This graph shows the total number of publications written about "Cholesterol, LDL" by people in this website by year, and whether "Cholesterol, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 0 | 1 | 1 | | 1986 | 1 | 1 | 2 | | 1987 | 0 | 2 | 2 | | 1988 | 0 | 3 | 3 | | 1989 | 0 | 1 | 1 | | 1990 | 0 | 3 | 3 | | 1991 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 1 | 1 | 2 | | 1995 | 2 | 5 | 7 | | 1996 | 1 | 3 | 4 | | 1997 | 2 | 3 | 5 | | 1998 | 2 | 4 | 6 | | 1999 | 0 | 4 | 4 | | 2000 | 3 | 8 | 11 | | 2001 | 2 | 13 | 15 | | 2002 | 5 | 7 | 12 | | 2003 | 7 | 7 | 14 | | 2004 | 4 | 7 | 11 | | 2005 | 6 | 4 | 10 | | 2006 | 6 | 9 | 15 | | 2007 | 8 | 8 | 16 | | 2008 | 8 | 16 | 24 | | 2009 | 9 | 7 | 16 | | 2010 | 6 | 4 | 10 | | 2011 | 2 | 9 | 11 | | 2012 | 7 | 5 | 12 | | 2013 | 7 | 5 | 12 | | 2014 | 8 | 9 | 17 | | 2015 | 3 | 12 | 15 | | 2016 | 2 | 7 | 9 | | 2017 | 2 | 5 | 7 | | 2018 | 7 | 2 | 9 | | 2019 | 1 | 4 | 5 | | 2020 | 1 | 3 | 4 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cholesterol, LDL" by people in Profiles.
-
Vallejo-Vaz AJ, Packard CJ, Ference BA, Santos RD, Kastelein JJP, Stein EA, Catapano AL, Pedersen TR, Watts GF, Ray KK. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Atherosclerosis. 2021 03; 320:1-9.
-
Raal FJ, Bahassi EM, Stevens B, Turner TA, Stein EA. Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2747-2755.
-
Szarek M, Amarenco P, Callahan A, Goldstein LB, Sillesen H, Welch KM. Reply: Hemorrhagic Stroke, All-Cause Death, and Intensive LDL-C Lowering: Evidence From SPARCL and Beyond. J Am Coll Cardiol. 2020 08 18; 76(7):886-888.
-
Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 05 05; 75(17):2110-2118.
-
Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, López JAG, Bray S, Kurtz CE, Hamer AW, Raal FJ. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020 02 18; 75(6):565-574.
-
Kar SP, Brenner H, Giles GG, Huo D, Milne RL, Rennert G, Simard J, Zheng W, Burgess S, Pharoah PDP. Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. Int J Epidemiol. 2019 10 01; 48(5):1727-1730.
-
Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
-
Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
-
Benes LB, Brummell K, Roth M, Shen L, Davidson MH. The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature. Cardiovasc Revasc Med. 2020 02; 21(2):200-204.
-
Sah RP, Sharma A, Nagpal S, Patlolla SH, Sharma A, Kandlakunta H, Anani V, Angom RS, Kamboj AK, Ahmed N, Mohapatra S, Vivekanandhan S, Philbrick KA, Weston A, Takahashi N, Kirkland J, Javeed N, Matveyenko A, Levy MJ, Mukhopadhyay D, Chari ST. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2019 05; 156(6):1742-1752.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|